[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-363974-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-363974-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","engineering-multimodal-nanomaterials-for-prostate-cancer-theranostics-design-principles-recent-advances-and-translational-challenges","Engineering Multimodal Nanomaterials for Prostate Cancer Theranostics: Design Principles, Recent Advances, and Translational Challenges","","Prostate cancer remains a major clinical challenge due to limits in early detection, tumor heterogeneity, therapeutic resistance, and metastatic progression. Engineering multimodal nanomaterials offers integrated platforms for molecular imaging, biomarker detection and liquid biopsy, targeted delivery, multimodal treatment, and therapy-response assessment. The review highlights engineering-oriented design relationships among material properties, targeting strategies, and stimulus-responsive release to improve diagnostic performance, therapeutic selectivity, and translational feasibility, with emphasis on PSMA-targeted systems. Translation is constrained by heterogeneous biodistribution, protein corona effects, nonspecific uptake, limited long-term biosafety, manufacturing complexity, and batch variability.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/engineering-multimodal-nanomaterials-for-prostate-cancer-theranostics-design-principles-recent-advances-and-translational-challenges/363974/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/engineering-multimodal-nanomaterials-for-prostate-cancer-theranostics-design-principles-recent-advances-and-translational-challenges/363974.png","ImageObject",300,407,{"name":42,"@type":43},"PakDamar76","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is prostate cancer difficult to manage clinically?","Question",{"text":63,"@type":64},"Prostate cancer is challenged by limitations in early detection, tumor heterogeneity, therapeutic resistance, and metastatic progression.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do multimodal nanomaterials support prostate cancer theranostics?",{"text":68,"@type":64},"They integrate molecular imaging, biomarker detection and liquid biopsy, targeted delivery, multimodal therapy, and assessment of therapeutic response.",{"name":70,"@type":61,"acceptedAnswer":71},"What factors currently limit clinical translation of these nanoplatforms?",{"text":72,"@type":64},"Key barriers include heterogeneous biodistribution, protein corona effects, nonspecific uptake, insufficient long-term biosafety data, manufacturing complexity, and batch-to-batch variability.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},363974,1791083542,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090893057,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","International Journal of Nanomedicine  \nOpen Access Full Text Article REVIEW Engineering Multimodal Nanomaterials for Prostate Cancer Theranostics: Design Principles, Recent Advances, and Translational Challenges Jia Wang 1 , *, Zhongsong Zhang 2 , *, Haihao Li 3 , *, Yuanyin Teng 4 , *, Bo Chen 5 , *, Jieming Zuo 3 , Xiangyun Li 3 , Peiqin Zhan 3 , Shi Fu 3 , Yongqiang Xu 6 , Lingxiang Wen 7 , Bing Wang8 , Yuanzhi Fu 9 , Kehan Qin 2 , Wujie Chen 3 , Yinglong Huang 3 , Yihui Shi 3 , Junhao Chen 3 , Junxian Zhao 6 1Department of Endocrinology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650101, People’s Republic of China; 2School of Clinical Medicine, Chengdu Medical College, Chengdu, 610550, People’s Republic of China; 3Department of Urology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People’s Republic of China; 4Institute of Hematology, Zhejiang University, Hangzhou, 310003, People’s Republic of China; 5Department of Urology, Qujing Second People’s Hospital, Qujing, Yunnan, People’s Republic of China; 6Department of Urology, 920th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army, Kunming, Yunnan, People’s Republic of China; 7School of Clinical Medicine, Kunming Medical University, Kunming, Yunnan, 650032, People’s Republic of China; 8Department of Hematology, Nanfang Hospital, Southern Medical University, Guangdong, 510000, People’s Republic of China; 9Department of Clinical Medicine, Kunming University of Science and Technology, Kunming, 650500, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Junhao Chen; Junxian Zhao, Email [1486132386@qq.com](1486132386@qq.com); [2040617986@qq.com](2040617986@qq.com)  \n\n| Abstract: Prostate cancer (PCa) remains a major clinical challenge because of limitations in early detection, tumor heterogeneity, therapeutic resistance, and metastatic progression. Nanomaterials provide versatile platforms for PCa theranostics by integrating molecular imaging, biomarker detection, targeted delivery, multimodal therapy, and therapeutic response assessment. This review summarizes recent advances in major nanomaterial platforms for PCa theranostics, including lipid-based nanomaterials, polymeric nanoparticles, gold nanoparticles (AuNPs), magnetic nanoparticles (MNPs), biomimetic nanoplatforms, and emerging smart nanocarriers, with emphasis on imaging enhancement, biosensing and liquid biopsy, targeted drug and nucleic acid delivery, phototherapy, sonodynamic and chemodynamic therapy (CDT), immunotherapy, and multimodal combination strategies. These advances reflect a shift from conventional single-function nanocarriers toward engineered multimodal theranostic systems that integrate molecular targeting, stimulus-responsive release, image-guided intervention, combination therapy, and therapeutic response monitoring. Unlike previous reviews that mainly describe nanomaterial categories or isolated applications, this review adopts an engineering-oriented design–function–application–translation framework to clarify how material properties, targeting strategies, and stimulus-responsive designs influence diagnostic performance, therapeutic selectivity, and clinical feasibility. Particular emphasis is placed on prostatespecific membrane antigen (PSMA)-targeted nanoplatforms as representative systems for theranostic integration. Current evidence suggests that nanoplatforms can improve tumor-selective accumulation, imaging sensitivity, biomarker detection, cargo stability, and intracellular delivery while reducing off-target toxicity. However, clinical translation remains limited by heterogeneous biodistribution, protein corona effects, nonspecific uptake, insufficient long-term biosafety data, manufacturing complexity, and batch-to-batch variability. Overall, nanomedicine may support more precise, minimally invasive, and integrated PCa management, but successful translati","cbCaio4sdNgEqCNf","https://ap.wps.com/l/cbCaio4sdNgEqCNf","pdf",5533213,37,"English","# Abstract\n# Introduction","[{\"question\":\"Why is prostate cancer difficult to manage clinically?\",\"answer\":\"Prostate cancer is challenged by limitations in early detection, tumor heterogeneity, therapeutic resistance, and metastatic progression.\"},{\"question\":\"How do multimodal nanomaterials support prostate cancer theranostics?\",\"answer\":\"They integrate molecular imaging, biomarker detection and liquid biopsy, targeted delivery, multimodal therapy, and assessment of therapeutic response.\"},{\"question\":\"What factors currently limit clinical translation of these nanoplatforms?\",\"answer\":\"Key barriers include heterogeneous biodistribution, protein corona effects, nonspecific uptake, insufficient long-term biosafety data, manufacturing complexity, and batch-to-batch variability.\"}]","Engineering Multimodal Nanomaterials for Prostate Cancer Theranostics: Design Principles, Recent Advances, and Translational Challenges | PDF",1790154712,93,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a620bfbd57999a77b5ba8c2e90f2b51f.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d05e35bdc43fd1b69615afb3d17b83a5.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86e737224aacad95278c8f3f829b913c.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35211e0df7ac1e300e7cacda5a5aeb27.webp",980,1268]